Compass Therapeutics Q1 net loss $10.8M; cash $156.3M; FDA Fast Track for CTX-009

Compass Therapeutics, Inc.

Net loss $10.8M ($0.08/share) vs $7.8M ($0.06) in Q1 2023; R&D expenses rose to $9.5M.
Cash and marketable securities $156.3M at March 31, 2024; cash runway into late 2026.
FDA Fast Track for CTX-009 in BTC; COMPANION-002 enrollment to complete mid-2024, data Q1 2025.
Stage 1 of COMPANION-003 (CRC) enrollment complete; top-line data expected by mid-2024.
CTX-8371 first patient dosed in April 2024; Phase 2 planned for CTX-471 in melanoma with biomarker.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Compass Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $10.8 million, EPS $0.08 per share of common stock.

Period: the quarter ended March 31, 2024
Net income: $10.8 million
EPS: $0.08 per share of common stock
Result: reported results

Exact text from the filing

On May 13, 2024, Compass Therapeutics, Inc. issued a press release announcing financial results for the quarter ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Compass Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-002784

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.